Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 |
Tel: | N/A |
Website: | https://www.kuraoncology.com |
IR: | See website |
Key People | ||
Troy E. Wilson Chairman of the Board, President, Chief Executive Officer | Kathleen Ford Chief Operating Officer | Stephen Dale Chief Medical Officer |
Brian Powl Chief Commercial Officer | Teresa Bair Chief Legal Officer, Secretary |
Business Overview |
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates. |
Financial Overview |
For the fiscal year ended 31 December 2023, Kura Oncology Inc revenues was not reported. Net loss increased 12% to $152.6M. Higher net loss reflects Discovery and development of precision medicines segment loss increase of 19% to $165.8M, United States segment loss increase of 19% to $165.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -$2.03 to -$2.08. |
Employees: | 142 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $932.25M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$164.96M as of Dec 31, 2023 |
Net annual income (TTM): | -$152.63M as of Dec 31, 2023 |
Free cash flow (TTM): | -$124.99M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 76,180,620 as of Apr 8, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |